The Food and Drug Administration (FDA) draft Guidance (Guidance) addressing the content and format of Dear Health Care Provider (DHCP) letters—which are sometimes called “Dear Doctor” letters—is the first substantive guidance from FDA on this issue.
Introducing PRO Compliance
The essential resource for in-house professionals
Become your target audience’s go-to resource for today’s hottest topics.
Understand your clients’ strategies and the most pressing issues they are facing.
Keep a step ahead of your key competitors and benchmark against them.
Power up your legal research with modern workflow tools, AI conceptual search and premium content sets that leverage Lexology's archive of 900,000+ articles contributed by the world's leading law firms.
Questions? Please contact [email protected]
Register
To view this article you need a PDF viewer such as Adobe Reader.
The Food and Drug Administration (FDA) draft Guidance (Guidance) addressing the content and format of Dear Health Care Provider (DHCP) letters—which are sometimes called “Dear Doctor” letters—is the first substantive guidance from FDA on this issue.
If you would like to learn how Lexology can drive your content marketing strategy forward, please email [email protected].
"Lexology is a valuable, trustworthy and informative source for domestic and International legal developments within a business related framework. The newsfeeds deliver high quality summaries from leading experts in a user-friendly format. Keep up the good work, it's most appreciated!."